| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We have suggested that CK1δ/ε play important physiological roles in both neuropathic and inflammatory pain signaling, which makes them useful targets for analgesic drug development. We have also identified several potential new CK1 inhibitors. TG003, one of these candidates, was suggested to have potent inhibitory effects on CK1 isoforms in vitro, and showed antinociceptive effects on acute and persistent inflammatory pain models in mice. Our data indicate that TG003 might be a promising lead compound for the development of CK1-targeted new analgesic drugs .
|
